The previous studies indicate that NSCLC with EGFR mutation or ALK fusion does not respond well to PD-1/PD-L1 monotherapy compared with EGFR- and ALK-wild-type NSCLC [25,27,28,82]. This evidence concerns the gene ALK and non-small cell lung carcinoma.